149 related articles for article (PubMed ID: 36523775)
1. Dynamics of price competition in Italian pharmaceutical off-patent market.
Perna S; Cangini A; Marini R; Guerrizio MA; Da Cas R; Traversa G; Trotta F
Front Med (Lausanne); 2022; 9():1045374. PubMed ID: 36523775
[TBL] [Abstract][Full Text] [Related]
2. Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands.
Boersma C; Klok RM; Bos JM; Naunton M; van den Berg PB; de Jong-van den Berg LT; Postma MJ
Appl Health Econ Health Policy; 2005; 4(3):191-6. PubMed ID: 16309337
[TBL] [Abstract][Full Text] [Related]
3. Impact of European pharmaceutical price regulation on generic price competition: a review.
Puig-Junoy J
Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
[TBL] [Abstract][Full Text] [Related]
4. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
[TBL] [Abstract][Full Text] [Related]
5. The impact of patent expiry on drug prices: insights from the Dutch market.
van der Schans S; Vondeling GT; Cao Q; van der Pol S; Visser S; Postma MJ; Rozenbaum MH
J Mark Access Health Policy; 2020 Dec; 9(1):1849984. PubMed ID: 33312457
[No Abstract] [Full Text] [Related]
6. [What is the real price of SOP and OTC drugs? Pilot study on paracetamol].
Milozzi F; Di Filippo A; Cangini A; Trotta F
Epidemiol Prev; 2023; 47(1-2):57-66. PubMed ID: 36727257
[TBL] [Abstract][Full Text] [Related]
7. Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.
Casanova-Juanes J; Mestre-Ferrandiz J; Espín-Balbino J
Health Policy; 2018 Dec; 122(12):1310-1315. PubMed ID: 30389186
[TBL] [Abstract][Full Text] [Related]
8. The Brazilian private pharmaceutical market after the first ten years of the generics law.
Bertoldi AD; Wagner AK; Emmerick ICM; Chaves LA; Stephens P; Ross-Degnan D
J Pharm Policy Pract; 2019; 12():18. PubMed ID: 31417682
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review.
Vondeling GT; Cao Q; Postma MJ; Rozenbaum MH
Appl Health Econ Health Policy; 2018 Oct; 16(5):653-660. PubMed ID: 30019138
[TBL] [Abstract][Full Text] [Related]
10. Do generics offer significant savings to the UK National Health Service?
Kanavos P
Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
[TBL] [Abstract][Full Text] [Related]
11. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
Kwon HY; Kim H; Godman B; Reich MR
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
[TBL] [Abstract][Full Text] [Related]
12. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure.
Magazzini L; Pammolli F; Riccaboni M
Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754
[TBL] [Abstract][Full Text] [Related]
13. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia.
Inotai A; Brixner D; Maniadakis N; Dwiprahasto I; Kristin E; Prabowo A; Yasmina A; Priohutomo S; Németh B; Wijaya K; Kalo Z
BMC Health Serv Res; 2018 Dec; 18(1):1003. PubMed ID: 30594250
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical pricing dynamics in an internal reference pricing system: evidence from changing drugs' reimbursements.
Costa E; Santos C
Eur J Health Econ; 2022 Dec; 23(9):1497-1518. PubMed ID: 35192093
[TBL] [Abstract][Full Text] [Related]
15. Measuring performance in off-patent drug markets: a methodological framework and empirical evidence from twelve EU Member States.
Kanavos P
Health Policy; 2014 Nov; 118(2):229-41. PubMed ID: 25201433
[TBL] [Abstract][Full Text] [Related]
16. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
[TBL] [Abstract][Full Text] [Related]
17. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
[TBL] [Abstract][Full Text] [Related]
18. Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose.
Bergman MA; Granlund D; Rudholm N
Int J Health Econ Manag; 2016 Sep; 16(3):201-214. PubMed ID: 27878673
[TBL] [Abstract][Full Text] [Related]
19. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
Roughead EE; Kim DS; Ong B; Kemp-Casey A
WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C.
Heath K
Clinicoecon Outcomes Res; 2018; 10():539-550. PubMed ID: 30288069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
